EMA recommends Shire's Gaucher drug; Neuralstem raises $10M;

@FierceBiotech: On its 10th birthday, the importance of sequencing is still debated. Article | Follow @FierceBiotech

 @JohnCFierce: Venter on sequencing: "I think it's far more important than walking on the Moon; not much has happened since walking on the Moon." | @JohnCFierce

> The EMA recommended approval of Shire's Gaucher's disease treatment Vpriv following an accelerated approval process. Report

> The first big pharma apps specially designed for Apple's iPad have started to emerge, with Pfizer and Sanofi leading the charge with upgrades to their existing iPhone apps. Report

> Neuralstem plans to raise $10 million in a registered direct offering. The company plans to proceeds for working capital and general corporate purposes. Neuralstem release

> ImmunoGen says partner Sanofi-Aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. The trial earns ImmunoGen a  $1 million milestone payment. Release

And Finally... BNet's Jim Edwards takes a look at me-too drugs being developed by several Big Pharma companies. Article